Christopher Haas, DO
Interventional Cardiology · Cumberland, MDNPI 1093786436
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Boston Scientific accounts for 62.4% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $856, 3.2 times the $264 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in MD, where the typical reported total is $7,370.
Across 115 payments — averaging $35.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$478
- Amgen$198
- Chiesi USA, Inc.$142
- E.r. Squibb & Sons, L.L.C.$133
- Abiomed$102
- plus $466 from 11 others
What the payments were for
- Food & beverage$4,026100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 43 | $2,518 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 23 | $478 |
| Amgen | 3 | $198 |
| Chiesi USA, Inc. | 9 | $142 |
| E.r. Squibb & Sons, L.L.C. | 8 | $133 |
| Abiomed | 1 | $102 |
| Lilly USA, LLC | 5 | $82 |
| Novo Nordisk | 4 | $66 |
| Cardiovascular Systems Inc. | 4 | $66 |
| AbbVie | 2 | $52 |
| AstraZeneca | 3 | $47 |
| Johnson & Johnson | 3 | $38 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Novartis | 2 | $32 |
| Merit Medical Systems Inc | 1 | $18 |
| Biotronik Inc. | 1 | $18 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EMBLEM MRI S-ICD$422
- WATCHMAN Access System$275
- LUX-Dx Insertable Cardiac Monitor$221
- KRYSTEXXA$122
- WATCHMAN FLX$120
- Watchman$107
- LifeVest$106
- Impella$102
How this compares
$4,038 in reported general payments places this provider in the 30th percentile of 71 interventional cardiology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 193 | $211,300 |
| EntrestoSacubitril/Valsartan | 138 | $176,002 |
| XareltoRivaroxaban | 45 | $50,203 |
| BrilintaTicagrelor | 40 | $36,314 |
| FarxigaDapagliflozin Propanediol | 42 | $34,333 |
| JardianceEmpagliflozin | 17 | $14,791 |
| Warfarin Sodium | 972 | $12,274 |
| DapagliflozinDapagliflozin Propanediol | 13 | $10,859 |
| Ranolazine ErRanolazine | 45 | $7,840 |
| Ezetimibe | 116 | $5,866 |
| Metoprolol Succinate | 315 | $5,828 |
| Rosuvastatin Calcium | 243 | $5,781 |
| ClopidogrelClopidogrel Bisulfate | 426 | $5,777 |
| Enoxaparin Sodium | 52 | $4,681 |
| Atorvastatin Calcium | 339 | $4,669 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $12 | $211,300193 claims |
| NovartisEntresto | $32 | $176,002138 claims |
| AstraZenecaBrilinta, Farxiga | $47 | $70,64682 claims |
| Johnson & JohnsonXarelto | $38 | $50,20345 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 71 interventional cardiology providers in Maryland.
Other interventional cardiology in Cumberland
- Vinay SatwahGreenbelt$679K
- Aloke FinnBaltimore$575K
- Michael ChenRockville$241K
- John WangBaltimore$138K
- Steven HearneSalisbury$100K
- Amir NajafiBel Air$82K
- Diljon ChahalBaltimore$78K
- Joseph CinderellaSalisbury$72K
- Ali TabrizchiBel Air$66K
- Homam IbrahimSilver Spring$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.